P
Prakash Kumar
Researcher at Department of Biotechnology
Publications - 12
Citations - 138
Prakash Kumar is an academic researcher from Department of Biotechnology. The author has contributed to research in topics: Leishmania donovani & Drug delivery. The author has an hindex of 6, co-authored 12 publications receiving 84 citations.
Papers
More filters
Journal ArticleDOI
Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.
Prakash Kumar,Pushkar Shivam,Saptarshi Mandal,Pragya Prasanna,Saurabh Kumar,Surendra Prasad,Ashish Kumar,Prolay Das,Vahab Ali,Shubhankar K. Singh,Debabrata Mandal +10 more
TL;DR: GNP-based delivery of AmB can be a better, cheaper, and safer alternative than available AmB formulations, and improved antileishmanial efficacy and reduced cytotoxicity.
Journal ArticleDOI
Hemoglobin guided nanocarrier for specific delivery of amphotericin B to Leishmania infected macrophage
TL;DR: A chitosan-chondroitin sulfate based nanodelivery vehicle has been introduced and Hemoglobin has been attached on the surface of the delivery system for specifically targeting the leishmania infected macrophage taking the advantage of Leishmania being highly auxotrophic for heme.
Journal ArticleDOI
Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis - A review.
Pragya Prasanna,Prakash Kumar,Saurabh Kumar,Vinod Kumar Rajana,Vishnu Kant,Surendra Prasad,Utpal Mohan,Velayutham Ravichandiran,Debabrata Mandal +8 more
TL;DR: In this article, the role of physicochemical properties of a nanoscale delivery system is discussed and different ways of nano-formulation delivery ranging from liposome, niosomes, polymeric, metallic, solid-lipid NPs were updated along with the possible mechanisms of action against the parasite.
Journal ArticleDOI
Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis.
Prakash Kumar,Partha Pratim Bose +1 more
TL;DR: A “ghost cell” strategy based on macrophage membrane-derived nanovesicle has been introduced as a specific carriage for amphotericin B and significantly improved the toxicity profile and lowered LD50 value of the drug compared to traditional way of its direct administration and widely accepted antileishmanial therapy, AmBisome.
Journal ArticleDOI
Concurrent visual diagnosis and susceptibility profiling of the first line drug against visceral leishmaniasis by plasmonic detection of PCR amplified genetic biomarker.
TL;DR: An easy, fast, sensitive and cheap visual diagnosis and SAG susceptibility profiling for leishmaniasis based on recently recognized genetic biomarker and gold nanoparticle based plasmonic detection phenomenon is reported.